

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K  
CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): July 9, 2026

**Biohaven Ltd.**

(Exact name of registrant as specified in its charter)

**British Virgin Islands**  
(State or other jurisdiction of incorporation)

**001-41477**  
(Commission File Number)

**Not applicable**  
(IRS Employer Identification No.)

**c/o Biohaven Pharmaceuticals, Inc.**  
**215 Church Street**  
**New Haven, Connecticut 06510**  
(Address of principal executive offices, including zip code)  
**(203) 404-0410**  
(Registrant's telephone number, including area code)  
**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Shares, no par value	BHVN	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 9, 2026, Biohaven Ltd. (the “Company”) and Bruce Car, Ph.D., mutually agreed that, effective July 13, 2026, Dr. Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer. As Chief Innovation Officer, Dr. Car will focus on advancing Biohaven’s scientific initiatives and external collaborations, including leading multiple assets under the Company’s collaboration with Bexorg, Inc. Dr. Car will continue to serve as an executive officer of the Company. In connection with this transition, David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, effective July 13, 2026. In this role, Dr. Pirman will lead the Company’s internal drug-discovery organization, overseeing research programs.

In connection with his transition to a part-time role, Dr. Car’s salary will be reduced by fifty percent (50%) to reflect his work schedule.

There are no arrangements or understandings between Dr. Car and any other persons pursuant to which he agreed to transition to a part-time role. There are no related party transactions between Dr. Car and the Company that would require disclosure under Item 401(a) of Regulation S-K.

A copy of the press release issued by the Company on July 9, 2026, announcing the transition of Dr. Car is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit Number</b>	<b>Exhibit Description</b>
99.1	<u>Press Release, Dated July 9, 2026, “Biohaven Announces Scientific Leadership Transitions”</u>
104	The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 9, 2026

### **Biohaven Ltd.**

By: /s/ Matthew Buten  
Matthew Buten  
Chief Financial Officer

## Biohaven Announces Scientific Leadership Transitions

- *David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery*
- *Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations*
- *Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer*

**NEW HAVEN, Conn., July 9, 2026** — Biohaven Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this role, Dr. Pirman will lead the Company’s internal drug-discovery organization, overseeing research programs.

Dr. Car is retiring as Chief Scientific Officer and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer, effective July 13, 2026. In this role, Dr. Car will focus on advancing Biohaven’s scientific initiatives and external collaborations including leading multiple assets under the Company’s collaboration with Bexorg, Inc. Dr. Car will continue to serve as an executive officer of the Company.

Warren Volles, General Counsel and Chief Legal Officer, has also been designated an executive officer of Biohaven and will continue to lead the Company’s legal function.

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, said, “We thank Bruce as he has played a central role in building Biohaven’s scientific foundation and helping translate discovery insights into multiple IND-stage programs across our portfolio. We are pleased that he will continue to bring his expertise to Biohaven in this new part-time role, with a particular focus on our collaboration with Bexorg. David’s promotion reflects his leadership and significant contributions to Biohaven’s discovery efforts, as well as his strong alignment with our continued focus on scientific innovation across our diverse portfolio of drug candidates. Together, these two executive transitions will position us to sustain our discovery momentum and pursue new CNS therapies grounded in human biology and translational innovation.”

Dr. Bruce Car added, “The timing of my retirement and transition reflects my complete confidence in Biohaven’s discovery research platforms and leadership, and genuine excitement for the future of the Biohaven portfolio.”

### **About the Biohaven–Bexorg Collaboration**

In June 2025, Biohaven and Bexorg, Inc., a New Haven-based techbio company, announced a multi-program research collaboration to identify, de-risk, and advance next-generation therapies for CNS disorders. Under the collaboration, Bexorg’s whole-brain discovery platform is used to demonstrate target engagement in relevant cell types and tissues and to generate biomarkers,

pharmacokinetic and pharmacodynamic relationships, and other mechanistic data supporting Biohaven preclinical programs.

## **About Biohaven**

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies for people with debilitating diseases, with a broad pipeline spanning neuroscience, immunology, and other therapeutic areas. For more information, visit [biohaven.com](http://biohaven.com).

## **Forward-Looking Statements**

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "potentially", "potentially groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

## **Contacts**

### **Investor Contact:**

Jennifer Porcelli  
Vice President, Investor Relations, Biohaven  
[jennifer.porcelli@biohavenpharma.com](mailto:jennifer.porcelli@biohavenpharma.com)  
+1 (201) 248-0741

### **Media Contact:**

Mike Beyer  
Sam Brown Healthcare Communications  
[mikebeyer@sambrown.com](mailto:mikebeyer@sambrown.com)  
+1 (312) 961-2502